Related Experiment Videos
A novel approach to antiviral therapy for influenza
1Biomolecular Research Institute, Parkville, Victoria, Australia. peter.colman@bioresi.com.au
The Journal of Antimicrobial Chemotherapy
|July 6, 2000
Summary
Novel sialic acid analogues, including zanamivir, effectively inhibit influenza neuraminidase. This antiviral strategy demonstrates broad efficacy against influenza A and B, with minimal risk of drug resistance.
Area of Science:
- Virology
- Biochemistry
- Drug Discovery
Background:
- Influenza neuraminidase is a key viral glycoprotein essential for releasing progeny virions.
- Neuraminidase activity facilitates viral spread and contributes to host viral burden.
Purpose of the Study:
- To design and evaluate novel sialic acid analogues as potent neuraminidase inhibitors.
- To develop effective antiviral agents against influenza.
Main Methods:
- Structure-based drug design utilizing neuraminidase and enzyme-product complex structures.
- In vitro and in vivo testing of designed sialic acid analogues.
- Formulation of zanamivir for inhalation delivery.
Main Results:
- Novel sialic acid analogues, particularly zanamivir, demonstrated potent inhibition of neuraminidase.
- Zanamivir showed broad-spectrum activity against influenza A and B neuraminidases.
- Inhibition of neuraminidase translated to antiviral activity in various models, including human influenza.
Conclusions:
- Zanamivir, a minimal modification of sialic acid, effectively inhibits influenza neuraminidase.
- The drug's design targeting strain-invariant amino acids minimizes resistance development.
- Inhaled zanamivir formulation achieves high local concentrations for maximal viral neuraminidase inhibition.